Article
A randomized, double blind, dose escalation, first time in human study to assess the safety, tolerability, pharmacokinetics, and antiviral activity of single doses of GSK2485852 in chronically infected hepatitis C subjects.
Clinical pharmacology in drug development - 1 Nov 2014
Wilfret David A, Walker Jill, Voitenleitner Christian, Baptiste-Brown Sharon, Lovern Mark, Kim Joseph, Adkison Kimberly, Shotwell Brad, Mathis Amanda, Moss Lee, Lee Daniel, Yu Lou, Gan Jianjun, Spaltenstein Andrew
Abstract excerpt
This first-time-in-human, randomized, double-blind, placebo-controlled, dose-escalation study assessed the safety, tolerability, pharmacokinetics, and antiviral activity of GSK2485852, a hepatitis C virus (HCV) NS5B inhibitor, in 27 chronically infected HCV genotype-1 subjects. Subjects received GSK2485852 70, 420, and 70 mg with a moderate fat/caloric meal. Safety, pharmacokinetics, antiviral activity, HCV...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.